Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
Status:
Terminated
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ibrutinib in treating B-cell
non-Hodgkin lymphoma that has returned or does not respond to treatment in patients with
human immunodeficiency virus (HIV) infection. Ibrutinib may stop the growth of cancer cells
by blocking some of the enzymes needed for cell growth. It is not yet known whether it is
safe for patients with HIV infection to receive ibrutinib while also taking anti-HIV drugs.